Rentosertib, developed by Insilico Medicine's AI, enters human clinical trial for the first time; 6 aging clocks measure decreased predicted age in patients
The drug, named Rentosertib, has a molecular structure generated with AI assistance. A new study published in Nature Biotechnology on Monday local time shows that patients treated with Rentosertib saw a decrease in age-related biomarkers, based on measurements from six "aging clocks."
Return to original text
A short introduction is retained here; the full text from the source website is not reposted. For specific wording and subsequent updates, please refer to the original article.
Open the original article on ITHome